AnGes, Inc. Logo

AnGes, Inc.

Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.

4563 | T

Overview

Corporate Details

ISIN(s):
JP3127700007
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ七丁目7番15号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AnGes, Inc., founded in 1999, is a biopharmaceutical company dedicated to the research and development of gene-based medicines. The company focuses on becoming a global leader in genetic pharmaceuticals by developing innovative treatments that harness the power of genes. Its core pipeline includes Hepatocyte Growth Factor (HGF) gene therapy products for blood vessel regeneration, DNA vaccines based on plasmid DNA technology, and NF-kB decoy oligonucleotides. AnGes actively engages in clinical studies and forms global alliances and manufacturing collaborations to advance its therapeutic programs and make novel treatments accessible to patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 07:30
Registration Form
有価証券届出書(参照方式)
Japanese 244.5 KB
2025-08-13 06:50
Interim Report
確認書
Japanese 8.9 KB
2025-08-13 04:19
Interim Report
半期報告書-第27期(2025/01/01-2025/12/31)
Japanese 488.0 KB
2025-03-31 04:52
Post-Annual General Meeting Information
臨時報告書
Japanese 25.5 KB
2025-03-31 03:22
Governance Information
内部統制報告書-第26期(2024/01/01-2024/12/31)
Japanese 23.7 KB
2025-03-31 03:18
Registration Form
確認書
Japanese 8.9 KB
2025-03-31 03:17
Registration Form
有価証券報告書-第26期(2024/01/01-2024/12/31)
Japanese 1.5 MB
2024-09-03 06:05
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 203.2 KB
2024-08-30 09:06
Registration Form
有価証券届出書(参照方式)
Japanese 381.2 KB
2024-08-14 02:28
Interim Report
確認書
Japanese 8.9 KB
2024-08-14 02:27
Interim Report
半期報告書-第26期(2024/01/01-2024/12/31)
Japanese 725.7 KB
2024-05-14 02:27
Report Publication Announcement
確認書
Japanese 8.9 KB
2024-05-14 02:25
Quarterly Report
四半期報告書-第26期第1四半期(2024/01/01-2024/03/31)
Japanese 457.7 KB
2024-03-29 01:45
Post-Annual General Meeting Information
臨時報告書
Japanese 24.0 KB
2024-03-29 01:43
Governance Information
内部統制報告書-第25期(2023/01/01-2023/12/31)
Japanese 23.6 KB

Automate Your Workflow. Get a real-time feed of all AnGes, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AnGes, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AnGes, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.
South Korea
078160
MediWound Ltd. Logo
Develops enzymatic therapies for non-surgical tissue repair in burns and chronic wounds.
United States of America
MDWD
Medizen Humancare Inc Co., Ltd Logo
Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.
South Korea
236340
Medy-Tox Inc. Logo
Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.
South Korea
086900
MeiraGTx Holdings plc Logo
Develops genetic medicines for eye, salivary gland, and CNS disorders using gene regulation tech.
United States of America
MGTX
Meito  Sangyo  Co., Ltd. Logo
Produces food products and specialty chemicals for industrial and pharmaceutical applications.
Japan
2207
Merck & Co., Inc. Logo
A global biopharma developing innovative medicines, vaccines, and animal health products.
United States of America
MRK
Mereo BioPharma Group plc Logo
A clinical-stage biopharma developing and commercializing novel therapies for rare diseases.
United States of America
MREO
Mersana Therapeutics, Inc. Logo
Developing innovative antibody-drug conjugates using proprietary platforms to treat cancer.
United States of America
MRSN
Merus N.V. Logo
Develops multispecific antibody therapies that harness the immune system to fight cancer.
United States of America
MRUS

Talk to a Data Expert

Have a question? We'll get back to you promptly.